Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis

Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter,
multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics
(PK) of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis
bronchiectasis (NCFBE).

Inclusion Criteria:

1. Clinical history consistent with NCFBE (cough, chronic sputum production and/or
recurrent respiratory infections)

2. Are current sputum producers with a history of chronic expectoration and able to
provide a sputum sample during Screening

3. Have at least 2 documented pulmonary exacerbations in the past 12 months before
Screening

Exclusion Criteria:

1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma

2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common
variable immunodeficiency, or alpha1-antitrypsin deficiency

3. Are current smokers

4. Are currently being treated for a nontuberculous mycobacterial lung infection,
allergic bronchopulmonary aspergillosis, or tuberculosis

5. Have any acute infections, (including respiratory infections)